「AI Dog Vaccine」 Principal Investigator Publicly Releases Full Technical Solution: 300GB Genetic Data, Three Chatbot Division of Labor, From Target Screening to Drug Administration Timeline

According to 1M AI News monitoring, Australian AI consulting firm founder Paul Conyngham has published a lengthy post on X, publicly revealing for the first time his complete technical proposal for designing a personalized mRNA cancer vaccine for his dog Rosie using an AI chatbot. Rosie, an 8-year-old Staffordshire Bull Terrier mix, was diagnosed with malignant mast cell cancer in May 2024, with veterinarians estimating only a few months left to live.

Conyngham, with no background in biology, relied on three AI chatbots, ChatGPT, Gemini, and Grok, throughout the entire process. He first utilized Professor Martin Smith from the Ramaciotti Centre at the University of New South Wales (UNSW) and the team at the Garvan Institute to conduct Rosie's whole genome sequencing and RNA sequencing, resulting in approximately 300GB of raw data. Subsequently, he used ChatGPT to design a bioinformatics analysis pipeline, employed AlphaFold 2 to model mutated protein structures, and ultimately identified a c-KIT gene mutation through cross-validation of DNA and RNA data, selecting 7 new antigen targets. Gemini Pro 2 was responsible for constructing a multi-epitope vaccine sequence, while Grok 3 carried out structural stability validation.

The vaccine was manufactured by the UNSW mRNA Research Institute's team led by Professor Pall Thordarson and administered by the team of Professor Rachel Allavena at the University of Queensland's School of Veterinary Science. The treatment regimen involved not only the vaccine but also a tripartite therapy designed with AI's assistance: the mRNA vaccine trained the immune system to recognize cancer cells, the tyrosine kinase inhibitor blocked cancer cell proliferation and angiogenesis being driven by the c-KIT mutation, and the PD-1 checkpoint inhibitor relieved the inhibitory signal of cancer cells on T cells. The dosing schedule of the three was planned with the assistance of ChatGPT and Gemini because immune-suppressing drugs and immune-activating vaccines cannot be used simultaneously.

Treatment began in December 2025, and three months later, two tumors on Rosie's legs had significantly shrunk, but one tumor on her hip did not respond. It was surgically removed and subjected to genomic analysis, which preliminarily indicated differences in its mutation characteristics from the cancer targeted by the vaccine design. Conyngham concluded that AI chatbots had given him "the ability of a research institute by himself," covering process planning, educational learning, technical troubleshooting, compliance documentation, and scientific design. He stated that he is evaluating the possibility of scaling up this process, saying, "It won't stop at one dog."

Experts caution that this is merely a single case study and not a controlled trial, thus not constituting evidence that AI can cure cancer.